Plus January PDUFA date for Biogen, Eisai Alzheimer’s therapy, and updates from Genentech, Sarepta, CytomX and more

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference

Plus FDA approves CTI’s pacritinib, Aurinia shares sink, Lexicon submission delayed, priority review for neoadjuvant Opdivo and more

Emerging Company Profile: CellPoint aims to broaden access to CAR Ts with point-of-care manufacturing platform

Moderna Inc. (NASDAQ:MRNA) will be the next company to bring a COVID-19 vaccine forward for authorization in adolescents, with plans to submit data from the Phase II/III TeenCOVE study of its COVID-19

Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s

AbbVie reaffirms its commitment to cancer, paying $750M up front for rights to a trio of Genmab bispecifics

How 2019 could yield first evidence ImmunoGen’s new growth strategy is working

Emerging science on adhesion molecules, RNA-binding proteins and more at ASH 2018